Extended Data Fig. 1: T cell markers and subset frequencies are comparable between WT and Slamf6−/− mice.
From: SLAMF6 as a drug-targetable suppressor of T cell immunity against cancer

a, Flow cytometry analyses of various cell surface markers on CD4+CD8− and CD4−CD8+ thymocytes from WT and Slamf6−/− mice. n = 4 (WT and Slamf6−/−). b, Same as (a), except that expression of CD5, CD44 and CD25 was evaluated on CD4+CD8−, CD4−CD8+, CD4−CD8− and CD4+CD8+ thymocytes. n = 4 (WT and Slamf6−/−). c, Total thymocyte numbers, as well as proportions and numbers of CD4+ and CD8+ T cells in thymus from WT and Slamf6−/− mice were determined. n = 4 (WT and Slamf6−/−). d, As in a, except that splenic T cells were analysed. n = 4 (WT and Slamf6−/−). e, As in c, except that splenic T cells were analysed. f,g, Proportions and numbers of regulatory T cells (Tregs) (f) and invariant (i) NKT cells (g) in spleen of WT and Slamf6−/− mice. n = 4 (WT and Slamf6−/−). h, Proportions and numbers of naïve (CD62LhiCD44lo), central memory (TCM; CD62LhiCD44hi) and effector-memory (TEM; CD62LloCD44hi) in CD4+ or CD8+ T cells from spleen of WT and Slamf6−/− mice. n = 4 (WT and Slamf6−/−). i, Flow cytometry analyses of the levels of SLAMF6 on subsets of splenic CD4+ or CD8+ T cells from WT and Slamf6−/− mice. n = 3 (WT and Slamf6−/−). j, Same as (i), except that the frequency of PD-1+ cells was analysed. n = 3 (WT and Slamf6−/−). Each symbol in a-j represents an individual mouse; error bars represent mean ± s.d. Numbers above data points represent p values. Two-sided unpaired Student’s t-test (a-j). n = 4 mice (a-h) or n = 3 mice (i-j) from 3 independent experiments.